- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| VASO Aktie jetzt für 0€ handeln | |||||
| 15.05. | Vaso Corporation Announces Financial Results for First Quarter of 2025 | 163 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., May 15, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional... ► Artikel lesen | |
| 31.03. | VASO Corp - 10-K, Annual Report | 1 | SEC Filings | ||
| 31.03. | Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year 2024 | 160 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., March 31, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services,... ► Artikel lesen | |
| 13.01. | Vaso Corporation Announces Executive Leadership Appointments & Names New Vice Chairman to the Board of Directors | 138 | GlobeNewswire (Europe) | PLAINVIEW, N.Y, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leader in human capital, information technology and MedTech, today announced new executive appointments... ► Artikel lesen | |
| 03.01. | VASO Corp - 8-K, Current Report | - | SEC Filings | ||
| 16.12.24 | Vaso Corporation CEO Reflects on a Year of Growth and Innovation in End-of-Year Letter Setting the Tone for a Promising 2025 | 138 | GlobeNewswire (Europe) | Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 NEWS RELEASE PLAINVIEW, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX:... ► Artikel lesen | |
| 14.11.24 | Vaso Corporation Announces Financial Results for Third Quarter 2024 | 154 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading medtech company with a diversified business portfolio in network and healthcare IT services, professional... ► Artikel lesen | |
| 19.09.24 | Vaso Corporation Announces Termination of Business Combination Agreement with Achari Ventures Holdings Corp. I | 165 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO) today announced that it has provided notice to Achari Ventures Holdings Corp. I ("Achari") to terminate... ► Artikel lesen | |
| 14.08.24 | Vaso Corporation Announces Financial Results for Second Quarter 2024 | 152 | GlobeNewswire (Europe) | High deferred revenue and backlog setting stage for 2024 revenue and income growth PLAINVIEW, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO) today reported its operating... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 25,535 | -5,34 % | Bayer - BAYN: Die DZ Bank erkennt positive Signale! | … aber Währungsrisiken! Pharma & Crop Science laufen bei Bayer (BAYN) offenbar besser als erwartet! Bayer (BAYN) - ISIN DE000BAY0017 Rückblick: Mit einem Kursplus von rund 37 Prozent in den vergangenen... ► Artikel lesen | |
| ASTRAZENECA | 118,65 | -1,17 % | EQS-Media: Onco-Innovations Ltd.: Attraktive Investmentperspektive: AstraZeneca zeigt Interesse an KI-Onkologie-Konsortium "PROmAI" | EQS-Media / 28.06.2025 / 14:56 CET/CEST
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass seine hundertprozentige Tochtergesellschaft... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 8,416 | +2,09 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 33,920 | -0,21 % | H.C. Wainwright bestätigt Kaufempfehlung für Ionis Pharmaceuticals-Aktie bei 50 US-Dollar | ||
| CSPC PHARMA | 0,851 | +0,76 % | CSPC PHARMA (01093): NOMINATION COMMITTEE - TERMS OF REFERENCE | ||
| SELLAS LIFE SCIENCES | 1,722 | +4,11 % | SELLAS Life Sciences wird in Russell 3000 und Russell 2000 Indizes aufgenommen | ||
| ACADIA PHARMACEUTICALS | 18,560 | -1,75 % | Acadia's 'very bullish' sales forecast restores some confidence on Wall Street | ||
| MADRIGAL PHARMACEUTICALS | 258,90 | +0,74 % | Madrigal, Viking among notable gainers after Altimmune's MASH setback | ||
| CATALYST PHARMACEUTICALS | 18,450 | -0,86 % | Catalyst Pharma: Viel Wachstum für wenig Geld? | Die meisten Biotech-Aktien sind vor allem eins: hochspekulativ. Catalyst Pharma beweist jedoch, dass es auch anders geht - mit realen Gewinnen und nachhaltigem Wachstum Den vollständigen Artikel lesen... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,080 | 0,00 % | ENZON PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| OPUS GENETICS | 0,845 | +0,48 % | Opus Genetics, Inc.: Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia | Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuitySafety profile consistent with previous clinical trials and no treatment-related... ► Artikel lesen | |
| CHUGAI PHARMACEUTICAL | 44,900 | +0,13 % | Roche-Tochter Chugai beantragt Zulassungserweiterung für Krebsmittel Alecensa | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2025 Financial Results on July 1, 2025 | Northvale, Northvale, New Jersey--(Newsfile Corp. - June 23, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic... ► Artikel lesen | |
| VIRACTA THERAPEUTICS | 0,019 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 10.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 10.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 10.02.2025ISIN NameES0105015012 LAR... ► Artikel lesen | |
| SAVARA | 1,930 | +2,66 % | Savara Inc.: Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences | Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced encore presentations of top-line data from the pivotal, Phase... ► Artikel lesen |
VASO CORPORATION gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VASO CORPORATION finden Sie auf Wallstreet Online.